F-group (family)
102.1.3.8 Mab-21_C
Ligands and drugs
400
Member domains
286
with ligand contacts (≤ 4 Å)
71.5% of members
162
with DrugDomain annotations
40.5% of members
63
with a DrugBank compound
15.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 102.1.3.8 belongs to X-group 102 HhH/H2TH, which binds 6.9 ligand superclasses per 20 proteins, narrower than 61% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02431 | CTP | Cytidine-5'-Triphosphate | 10 |
| DB04137 | GTP | Guanosine-5'-Triphosphate | 10 |
| DB00171 | ATP | ATP | 7 |
| DB16833 | ADP | Adenosine disphosphate | 7 |
| DB01972 | 5GP | Guanosine-5'-Monophosphate | 5 |
| DB04315 | GDP | Guanosine-5'-Diphosphate | 5 |
| DB00131 | AMP | Adenosine phosphate | 3 |
| DB02596 | APC | alpha,beta-Methyleneadenosine 5'-triphosphate | 2 |
| DB04005 | UTP | Uridine 5'-triphosphate | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 249 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 38 |
| 1SY | cGAMP | 12 |
| GTP | GUANOSINE-5'-TRIPHOSPHATE | 11 |
| CTP | CYTIDINE-5'-TRIPHOSPHATE | 10 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 7 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 5 |
| GDP | GUANOSINE-5'-DIPHOSPHATE | 5 |
| OKR | [[(2~{R},3~{R},4~{R},5~{R})-5-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-4-[[(2~{R},3~{S},4~{R},5~{R})-5-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-3-oxidanyl-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] phosphono hydrogen phosphate | 5 |
| YP8 | (8S)-5-benzyl-2-({[(5P)-2-chloro-5-(1-methyl-1H-pyrazol-3-yl)phenyl]methyl}amino)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | 5 |
| AEV | 2-(4,5-dichloro-1H-benzimidazol-2-yl)-5-methyl-4-[(1R)-3-oxo-1,3-dihydro-2-benzofuran-1-yl]-1,2-dihydro-3H-pyrazol-3-one | 4 |
| KHM | (1R,2S)-2-[(7-hydroxy-5-phenylpyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]cyclohexane-1-carboxylic acid | 4 |
| A1EAM | (4~{S},5~{R})-2-[4,5-bis(chloranyl)-1~{H}-benzimidazol-2-yl]-5-methyl-4-[(1~{S})-3-oxidanylidene-1~{H}-2-benzofuran-1-yl]pyrazolidin-3-one | 3 |
| JUJ | 1-[9-(6-aminopyridin-3-yl)-6,7-dichloro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl]-2-hydroxyethan-1-one | 3 |
| LLS | (3~{S})-3-[1-[4,5-bis(chloranyl)-1~{H}-benzimidazol-2-yl]-3-methyl-5-oxidanyl-pyrazol-4-yl]-3~{H}-2-benzofuran-1-one | 3 |
| YM9 | (5M)-5-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-7-carboxylic acid | 3 |
| YMO | (8S)-2-{[(3-fluoro[1,1'-biphenyl]-4-yl)methyl]amino}-5-propyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | 3 |
| YPU | 5-bromo-N-{[(5P)-2-fluoro-5-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}-2-hydroxybenzamide | 3 |
| 0XE | 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid | 2 |
| 1YC | 2-amino-9-[(1R,3R,6R,8R,9R,11S,14R,16R,17R,18R)-16-(6-amino-9H-purin-9-yl)-3,11,17,18-tetrahydroxy-3,11-dioxido-2,4,7,10,12,15-hexaoxa-3,11-diphosphatricyclo[12.2.1.1~6,9~]octadec-8-yl]-1,9-dihydro-6H-purin-6-one | 2 |